{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(6)"],"submitter":["Krejsa CM"],"pubmed_abstract":["Rituximab, a monoclonal antibody targeting CD20 on B cells, is currently used to treat many subtypes of B cell lymphomas. However, treatment is not curative and response rates are variable. Recombinant interleukin-21 (rIL-21) is a cytokine that enhances immune effector function and affects both primary and transformed B cell differentiation. We hypothesized that the combination of rIL-21 plus rituximab would be a more efficacious treatment for B cell malignancies than rituximab alone. We cultured human and cynomolgus monkey NK cells with rIL-21 and found that their activity was increased and proteins associated with antibody dependent cytotoxicity were up-regulated. Studies in cynomolgus monkeys modeled the effects of rIL-21 on rituximab activity against CD20 B cells. In these studies, rIL"],"journal":["PloS one"],"pagination":["e67256"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3692496"],"repository":["biostudies-literature"],"pubmed_title":["Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models."],"pmcid":["PMC3692496"],"pubmed_authors":["Roque R","Ren HP","Bannink KM","Sivakumar PV","Kindsvogel W","Shiota F","Heipel M","Johnson R","Chin L","Foster D","Henderson K","Clegg C","Hughes SD","Waggie K","Wagener F","Barahmand-Pour F","Krejsa CM","Heffernan J","Ponce R","Hill J","Holly RD"],"additional_accession":[]},"is_claimable":false,"name":"Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.","description":"Rituximab, a monoclonal antibody targeting CD20 on B cells, is currently used to treat many subtypes of B cell lymphomas. However, treatment is not curative and response rates are variable. Recombinant interleukin-21 (rIL-21) is a cytokine that enhances immune effector function and affects both primary and transformed B cell differentiation. We hypothesized that the combination of rIL-21 plus rituximab would be a more efficacious treatment for B cell malignancies than rituximab alone. We cultured human and cynomolgus monkey NK cells with rIL-21 and found that their activity was increased and proteins associated with antibody dependent cytotoxicity were up-regulated. Studies in cynomolgus monkeys modeled the effects of rIL-21 on rituximab activity against CD20 B cells. In these studies, rIL","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013","modification":"2025-06-01T12:27:40.767Z","creation":"2025-06-01T12:27:40.767Z"},"accession":"S-EPMC3692496","cross_references":{"pubmed":["23825648"],"doi":["10.1371/journal.pone.0067256"]}}